Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice
Autore:
Ni, WH; Egashira, K; Kitamoto, S; Kataoka, C; Koyanagi, M; Inoue, S; Imaizumi, K; Akiyama, C; Nishida, K; Takeshita, K;
Indirizzi:
Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Fukuoka 812, Japan Kyushu Univ Fukuoka Japan 812 i, Dept Cardiovasc Med, Fukuoka 812, Japan Kyushu Univ, Div Bioresource & Bioenvironm Sci, Nutr Chem Lab, Fukuoka 812, Japan Kyushu Univ Fukuoka Japan 812 onm Sci, Nutr Chem Lab, Fukuoka 812, Japan Daiichi Pharmaceut Co Ltd, New Prod Res Labs, Tokyo, Japan Daiichi Pharmaceut Co Ltd Tokyo Japan , New Prod Res Labs, Tokyo, Japan
Titolo Testata:
CIRCULATION
fascicolo: 16, volume: 103, anno: 2001,
pagine: 2096 - 2101
SICI:
0009-7322(20010424)103:16<2096:NACPGT>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
SMOOTH-MUSCLE CELLS; APOE-DEFICIENT MICE; LESIONS; EXPRESSION; GLOMERULONEPHRITIS; DIFFERENTIATION; CHEMOKINES; RECEPTOR; MCP-1; RATS;
Keywords:
apolipoproteins; atherosclerosis; gene therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Egashira, K Kyushu Univ, Grad Sch Med, Dept Cardiovasc Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan Kyushu Univ 3-1-1 Maidashi Fukuoka Japan 8128582 28582, Japan
Citazione:
W.H. Ni et al., "New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice", CIRCULATION, 103(16), 2001, pp. 2096-2101

Abstract

Background-Monocyte recruitment into the arterial wall and its activation may be the central event in atherogenesis. Monocyte chemoattractant protein-1 (MCP-1) is an important chemokine for monocyte recruitment, and its receptor (CCR2) may mediate such in vivo response, Although the importance of the MCP-1/CCR2 pathway in atherogenesis has been clarified, it remains unanswered whether postnatal blockade of the MCP-1 signals could be a unique site-specific gene therapy,Methods and Results-We devised a new strategy for anti-MCP-1 gene therapy to treat atherosclerosis by transfecting an N-terminal deletion mutant of the human MCP-1 gene into a remote organ (skeletal muscle) in apolipoproteinE-knockout mice. This strategy effectively blocked MCP-1 activity and inhibited the formation of atherosclerotic lesions but had no effect on serum lipid concentrations. Furthermore, this strategy increased the lesional extracellular matrix content. Conclusions-We conclude that this anti-MCP-1 gene therapy may serve not only to reduce atherogenesis but also to stabilize vulnerable atheromatous plaques, This strategy may be a useful and feasible form of gene therapy against atherosclerosis in humans.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 01:39:03